vaccine-safety
Does a COVID mRNA booster raise myocarditis risk?
Open access · cc by · source: Europe PMC
In England, myocarditis admissions rose mainly in males 16–39 within 0–6 days after mRNA doses (highest after dose 2); boosters still elevated risk but prior infection lowered vaccine-associated RIs.
Key findings
2,284 myocarditis and 1,651 pericarditis admissions. Elevated vaccine RIs mainly in 16–39-year-olds 0–6 days post-dose, especially males. ChAdOx1-S elevation only after first dose (RI 5.23). Prior infection lowered second-dose RIs; infection itself raised risk over 1–27 days.
Methodology
Ran a nationwide self-controlled case series comparing admission risk windows after BNT162b2, mRNA-1273, and ChAdOx1-S doses and after SARS-CoV-2 infection, stratified by age, sex, dose, and prior infection.
Limitations
Hospital-admission SCCS estimates rare absolute risks incompletely for mild outpatient cases; does not weigh COVID benefits vs risks for individuals.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.